http://purl.org/np/RA8wM4w_In... RA8wM4w_In

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T12:53:48.673Z

http://purl.org/np/RA8wM4w_In... RA8wM4w_In

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T12:53:48.673011

Elif Ozkan

2022-10-13T12:53:48.673Z

http://purl.org/np/RA8wM4w_In... RA8wM4w_In

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Levosimendan is indicated for short term treatment of acutely decompensated severe chronic heart failure (CHF) Also being investigated for use/treatment in heart disease. Also being looked at for treatment of heart disease in cardihesis and other forms of heart failure in the U.S., Europe and Asia. The drug is currently being tested for its use in the United States and Europe.

Elif Ozkan

2022-10-13T12:53:48.673Z